期刊文献+

HE_4、CA_(125)和D-dimer检测在卵巢癌早期诊断筛查中的应用价值 被引量:6

Application value of HE_4,CA_(125) and D-dimer in early diagnosis of ovarian cancer
下载PDF
导出
摘要 目的:探讨HE_4、CA_(125)和D-dimer在卵巢癌早期诊断筛查中的应用价值。方法:选择卵巢癌患者69例(卵巢癌组),良性卵巢囊肿患者65例(良性组),另外选择健康体检女性63例(健康组),分别监测三组的血清指标HE_4、CA_(125)和D-dimer,分析单项及联合检测的诊断效能。结果:卵巢癌组的HE_4、CA_(125)和D-dimer水平显著高于良性组和健康组(P<0.05),良性组的HE_4水平显著高于健康组(P<0.05),良性组和健康组的CA_(125)和D-dimer水平比较差异无统计学意义(P>0.05)。CA_(125)+HE_4联合检测的敏感度90.31%,高于HE 488.93%,CA_(125)73.71%以及D-dimer64.89%,而CA_(125)+HE_4+D-dimer联合检测的敏感度94.87%,不仅高于三项单独检测,还高于CA_(125)+HE_4联合检测90.31%。结论:血清指标HE_4、CA_(125)和D-dimer联合检测可提高卵巢癌早期筛查的准确度,从而提高诊断准确率,对卵巢癌的早期治疗及预后非常有重要意义。 Objective:To investigate the value of HE4,CA 125 and D-dimer in early diagnosis of ovarian cancer.Methods:69 cases of patients with ovarian cancer(ovarian cancer group),65 cases of benign ovarian cyst patients(benign group),another 63 cases of healthy women(healthy group),three groups of members of the serum HE 4,CA 125 and D-dimer were compared,and analysis of diagnostic efficacy of single or combined detection of.Results:the ovarian cancer group HE 4,CA 125 and D-dimer levels were significantly higher than benign group and healthy group(P<0.05),benign group the level of HE 4 was significantly higher than that of the control group(P<0.05),no statistical significance in benign group and healthy group of CA 125 and D-dimer level difference(P>0.05).The combined detection sensitivity of CAI 125+HE 4 was 90.31%,higher than the HE 4 88.93%,CA 125 73.71%and D-dimer 64.89%,and the combined detection sensitivity of CAI 125+HE 4+D-dimer was 94.87%,three was not only higher than the single detection,combined detection of CAI 125+HE 4 is higher than 90.31%.Conclusion:the combined detection of serum HE 4,CA 125 and D-dimer can improve the accuracy of early screening for ovarian cancer,so as to improve the accuracy of diagnosis,which is of great significance for the early treatment and prognosis of ovarian cancer.
作者 苏媛媛 李静 梁义娟 Su Yuanyuan;Li Jing;Liang Yijuan(Department of Obstetrics and Gynecology,Affiliated Hospital of Hebei University,Baoding 071000)
出处 《陕西医学杂志》 CAS 2018年第3期368-370,共3页 Shaanxi Medical Journal
关键词 卵巢肿瘤/诊断 @附睾分泌蛋白质类/分 @CA-125抗原 @D二聚体 Ovarian neoplasms/diagnosis Epididymal secretory/analysis @CA 125 Antigen @D-dimer
  • 相关文献

参考文献15

二级参考文献118

  • 1Joshua G Cohen,Matthew White,Ana Cruz,Robin Farias-Eisner.WJBC 5^(th) Anniversary Special Issues(2): Proteomics In 2014, can we do better than CA125 in the early detection of ovarian cancer?[J].World Journal of Biological Chemistry,2014,5(3):286-300. 被引量:18
  • 2韩德民,黄志刚,张伟,于振坤,王琪,倪鑫,陈晓红,潘锦华,王鸿.重组人p53腺病毒注射液治疗喉癌的Ⅰ期临床试验及追踪观察[J].中华医学杂志,2003,83(23):2029-2032. 被引量:60
  • 3陈传本,潘建基,徐鹭英.重组人p53腺病毒注射液结合放射治疗鼻咽癌Ⅱ期临床试验观察[J].中华医学杂志,2003,83(23):2033-2035. 被引量:52
  • 4Gao AH, Zhang L, Chen X, et al. Inhibition of ovarian cancer pro- liferation and invasion by pachymic acid[ J]. Int J Clin Exp Pathol, 2015, 8(2) : 2235 -2241.
  • 5Zhou J, Gong G, Tan H, et al. Urinary microRNA -30a -5p is a potential biomarker for ovarian serous adenocarcinoma [ J ]. Oncol Rep, 2015, 33(6) : 2915 -2923.
  • 6Chen Y, Watng X, Liu T, et al. Highly effective antiangiogenesis via magnetic mesoporous silica - based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy[ J ]. Int J Nano- medicine, 2015, 10 : 2579 - 2594.
  • 7Azzam AZ, Hashad DI, Kamel NA. Evaluation of HE4 as an extra- biomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward? [ J], Arch Gynecol Obstct, 2013, 288 (1): 167-172.
  • 8Dohmoto K, Hojo S, Fujita J, et al. Mechanisms of the release of CYFRA21 -1 in human lung cancer cell lines[ J]. Lung Cancer, 2000, 30 ( 1 ) : 55 - 63.
  • 9Stender MT, Fmkjaer JB, Hagedorn NTS, et al. Combined use of clinical pre - test probability and D - dimer test in the diagnosis of preoperative deep venous thrombosis in eolorectal cancer patients [J]. Thromb Haemost, 2008, 99(2) : 396 -400.
  • 10Cramer DW, Bast RC Jr, Berg CD, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens [J]. Cancer Prev Res (Phila), 2011, 4: 365-374.

共引文献198

同被引文献78

引证文献6

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部